RWE

Patient Engagement Solutions Market Worth $41.8 Billion | MarketsandMarkets

Retrieved on: 
Friday, December 15, 2023

In 2023, the software segment is estimated to account for the largest share of the patient engagement solutions market.

Key Points: 
  • In 2023, the software segment is estimated to account for the largest share of the patient engagement solutions market.
  • In terms of delivery mode, the patient engagement solutions market is categorized into on-premise and cloud-based/web-based modes.
  • Patient Engagement Solutions Market Dynamics:
    Key Market Players of Patient Engagement Solutions Industry:
    Prominent players in patient engagement solutions market are McKesson Corporation (US), Veradigm (US), Oracle Corporation (US), Merative (US), Epic Systems Corporation (US), Orion Health (New Zealand), GetWellNetwork (US), athenahealth (US), Oneview Healthcare (Ireland), MEDITECH (US), IQVIA (US), Get Real Health (US), Cognizant (US), Harris Healthcare (US), Kareo (US), CureMD Healthcare (US), eClinicalWorks (US), and Lincor Solutions (US), AdvancedMD (US), Luma Health Inc. (US), WellStack(US), Vivify Health (US), Medhost (US), MEDISYSINC (US), and  Patient point LLC (US).
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the patient engagement solutions market.

Patient Engagement Solutions Market Worth $41.8 Billion | MarketsandMarkets

Retrieved on: 
Friday, December 15, 2023

In 2023, the software segment is estimated to account for the largest share of the patient engagement solutions market.

Key Points: 
  • In 2023, the software segment is estimated to account for the largest share of the patient engagement solutions market.
  • In terms of delivery mode, the patient engagement solutions market is categorized into on-premise and cloud-based/web-based modes.
  • Patient Engagement Solutions Market Dynamics:
    Key Market Players of Patient Engagement Solutions Industry:
    Prominent players in patient engagement solutions market are McKesson Corporation (US), Veradigm (US), Oracle Corporation (US), Merative (US), Epic Systems Corporation (US), Orion Health (New Zealand), GetWellNetwork (US), athenahealth (US), Oneview Healthcare (Ireland), MEDITECH (US), IQVIA (US), Get Real Health (US), Cognizant (US), Harris Healthcare (US), Kareo (US), CureMD Healthcare (US), eClinicalWorks (US), and Lincor Solutions (US), AdvancedMD (US), Luma Health Inc. (US), WellStack(US), Vivify Health (US), Medhost (US), MEDISYSINC (US), and  Patient point LLC (US).
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the patient engagement solutions market.

Sandbrook Capital Raises $2.1 Billion for Climate Infrastructure

Retrieved on: 
Thursday, December 14, 2023

STAMFORD, Conn., Dec. 14, 2023 /PRNewswire/ -- Sandbrook Capital, a private investment firm dedicated to transforming the world's energy infrastructure, today announced the final closing of Sandbrook Climate Infrastructure Fund I at its hard cap of $1.5 billion. The fund, which significantly exceeded its $1.0 billion target, represents one of the largest emerging manager vehicles focused on energy transition infrastructure. The firm now manages $2.1 billion in limited partner capital, including associated co-investment vehicles.

Key Points: 
  • STAMFORD, Conn., Dec. 14, 2023 /PRNewswire/ -- Sandbrook Capital, a private investment firm dedicated to transforming the world's energy infrastructure, today announced the final closing of Sandbrook Climate Infrastructure Fund I at its hard cap of $1.5 billion.
  • The fund, which significantly exceeded its $1.0 billion target, represents one of the largest emerging manager vehicles focused on energy transition infrastructure.
  • The firm now manages $2.1 billion in limited partner capital, including associated co-investment vehicles.
  • Sandbrook's founders have been investing together for nearly 15 years and bring decades of experience in the renewable energy sector.

Havfram Wind signs contract with RWE for turbine transport and installation support for Nordseecluster offshore wind projects

Retrieved on: 
Wednesday, December 13, 2023

Havfram Wind is to transport and support the installation of 104 Vestas offshore wind turbines with a capacity of 15 megawatts each, which are to be installed throughout two construction phases.

Key Points: 
  • Havfram Wind is to transport and support the installation of 104 Vestas offshore wind turbines with a capacity of 15 megawatts each, which are to be installed throughout two construction phases.
  • Both of Havfram Wind's newbuild state-of-the-art Wind Turbine Installation Vessels will be utilised throughout both phases.
  • Even Larsen, CEO of Havfram Wind stated, "We are very pleased to successfully conclude the negotiations with RWE for the Nordseecluster projects.
  • The agreement with Havfram Wind, which encompasses all four projects, attests to the efficiency of concentrating activities such as procurement."

Inovalon Applauded by Frost & Sullivan for Improving Healthcare Delivery, Patient Outcomes, and Data Security with Its Inovalon ONE® Platform

Retrieved on: 
Monday, December 11, 2023

SAN ANTONIO, Dec. 11, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare analytics and real-world evidence (RWE) information technology solutions industry and, based on its analysis, recognizes Inovalon with the 2023 North American Product Leadership Award. The cloud-based software-as-a-service (SaaS) provider empowers healthcare organizations with data-driven insights to improve clinical, operational, and financial performance. Through the Inovalon ONE® Platform and its Insights solutions, Inovalon supports payers, providers, pharmacies, and life sciences organizations using real-world data (RWD) and advanced analytics to enhance healthcare outcomes and economics.

Key Points: 
  • Inovalon ONE® Platform seamlessly aggregates, standardizes, and analyzes diverse data to gain meaningful insights, support evidence-based decision-making, and offer data security and privacy.
  • Through the Inovalon ONE® Platform and its Insights solutions, Inovalon supports payers, providers, pharmacies, and life sciences organizations using real-world data (RWD) and advanced analytics to enhance healthcare outcomes and economics.
  • The cloud-based Inovalon ONE Platform provides SaaS solutions leveraging the company's national-scale connectivity, real-time primary source data, and advanced analytics to provide actionable insights that inform and expedite patient care and business strategies.
  • Using Inovalon's MORE2 Registry®, the nation's largest healthcare dataset originating from longitudinally matched and primary source data, the platform helps achieve data integration, compliance, and security.

Inovalon Applauded by Frost & Sullivan for Improving Healthcare Delivery, Patient Outcomes, and Data Security with Its Inovalon ONE® Platform

Retrieved on: 
Monday, December 11, 2023

SAN ANTONIO, Dec. 11, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare analytics and real-world evidence (RWE) information technology solutions industry and, based on its analysis, recognizes Inovalon with the 2023 North American Product Leadership Award. The cloud-based software-as-a-service (SaaS) provider empowers healthcare organizations with data-driven insights to improve clinical, operational, and financial performance. Through the Inovalon ONE® Platform and its Insights solutions, Inovalon supports payers, providers, pharmacies, and life sciences organizations using real-world data (RWD) and advanced analytics to enhance healthcare outcomes and economics.

Key Points: 
  • Inovalon ONE® Platform seamlessly aggregates, standardizes, and analyzes diverse data to gain meaningful insights, support evidence-based decision-making, and offer data security and privacy.
  • Through the Inovalon ONE® Platform and its Insights solutions, Inovalon supports payers, providers, pharmacies, and life sciences organizations using real-world data (RWD) and advanced analytics to enhance healthcare outcomes and economics.
  • The cloud-based Inovalon ONE Platform provides SaaS solutions leveraging the company's national-scale connectivity, real-time primary source data, and advanced analytics to provide actionable insights that inform and expedite patient care and business strategies.
  • Using Inovalon's MORE2 Registry®, the nation's largest healthcare dataset originating from longitudinally matched and primary source data, the platform helps achieve data integration, compliance, and security.

Energy Companies from Europe, North America, Asia, and Middle East Won Honors at S&P Global Commodity Insights' 25th Annual Platts Global Energy Awards

Retrieved on: 
Friday, December 8, 2023

NEW YORK, Dec. 7, 2023 /PRNewswire/ -- S&P Global Commodity Insights, the leading global independent provider of data, insights, analysis and benchmark prices for the commodities, energy and energy transition markets, tonight honored industry excellence in 21 performance categories and winners from nearly a dozen countries at the Platts Global Energy Awards gala held at the Cipriani Wall Street in downtown New York City. The Awards program, now in its 25th year and often described as the "Oscars of the energy industry", recognizes corporate and individual innovation, leadership, and performance in the energy and petrochemicals sectors, and bestowed honors on companies from Belgium, Germany, India, Singapore, Thailand, UK, Ukraine, United Arab Emirates and US. For a third consecutive year, CNBC correspondent Kristina Partsinevelos, whose reporting appears on television and CNBC's digital platforms, emceed the event, continuing a long history of CNBC guest hosts at the Awards gala.

Key Points: 
  • Among his many appointments, judges noted Nasser's global influence and esteem, as a member of energy thought leadership and financial institutions.
  • An independent panel of judges chose the winners of the 2023 Platts Global Energy Awards from finalists selected from nominations that represented 33 different countries.
  • Jeanette Gitobu of Belgium's Global Wind Energy Council was singled out from her peers for Rising Star Individual Award.
  • For details of these and other Awards winners of this year's Platts Global Energy Awards, access the December issue of the S&P Global Commodity Insights Magazine or visit the Platts Global Energy Awards website .

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App

Retrieved on: 
Thursday, December 7, 2023

LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
  • The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
  • Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research.
  • With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support.

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App

Retrieved on: 
Thursday, December 7, 2023

LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
  • The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
  • Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research.
  • With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support.

Deep 6 AI Expands Its Recruitment Acceleration Solution for Life Sciences to Shorten the Time from Determining Patient Eligibility to Enrollment

Retrieved on: 
Wednesday, December 6, 2023

PASADENA, Calif., Dec. 6, 2023 /PRNewswire/ -- Deep 6 AI, the leader in AI-powered precision research software which de-risks and accelerates clinical trials for research sites and sponsors, today announced the expansion of its Recruitment Acceleration solution, known for leveraging artificial intelligence (AI) to mine the industry's deepest source of real-time electronic medical record (EMR) data to precisely find patients for trials. With the expanded solution, life sciences companies can share AI-matched patient cohorts with IRB-approved site staff across the Deep 6 AI ecosystem. This allows sites to identify each patient, validate their eligibility with evidence in the EMR, and track their recruitment statuses faster and more precisely, shortening the time to enrollment.

Key Points: 
  • With the expanded solution, life sciences companies can share AI-matched patient cohorts with IRB-approved site staff across the Deep 6 AI ecosystem.
  • This allows sites to identify each patient, validate their eligibility with evidence in the EMR, and track their recruitment statuses faster and more precisely, shortening the time to enrollment.
  • Deep 6 AI also offers expanded access to all these precision-matched, trial-eligible patients, across all site locations and physicians.
  • Deep 6 AI's life sciences solutions also provide access to advanced genomics and diversity, equity, and inclusion (DE&I) insights.